Why NFX Invested in Cyclana Bio: A Bioplatform Building Physiologically Accurate Human Tissue Models

https://nfx.com/post/cyclana-bio
  • Cyclana Bio builds human tissue models for drug discovery, starting with endometriosis.
    • £5M Pre-Seed co-led by NFX and Eka Ventures; Wilbe and Cocoa VC also in.
    • First full human tissue model for endometriosis — no competitor exists.
  • Endometriosis: 1 in 10 women, no cure, $2B symptom-treatment market.
    • Models capture ECM invasion + microenvironmental inflammation drivers.
  • Platform extends to uterine cancer, IBD, osteoarthritis; women’s health hits $30B by 2030.
  • All three founders ex-Altos Labs; two Cambridge PhDs, one Cambridge professor.
    • Prof. Kevin Chalut (CSO): stem cell biology, former Altos Labs Principal Investigator.
    • Dr. Griffiths (CTO): single-cell sequencing PhD, led ML epigenetics at Altos Labs.

Omri Drory, Ph.D. (NFX General Partner) · 2025-10-21 · Read on nfx.com

Type Link
Added Oct 21, 2025
Modified Apr 15, 2026
💭 Thinking 15 items